RxPONDER
clinical trial key findings presented at San Antonio Breast Cancer Symposium
December 8-11, 2020
RxPONDER at SABCS 2020

The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX®test


RxPONDER clinical trial key findings*


  • The majority of postmenopausal HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1-3 positive nodes and Recurrence Score® results 0-25 significantly benefit from chemotherapy
  • RxPONDER study results are expected to be practice-changing for postmenopausal N1 HR+, HER2-, early breast cancer patients

* Kalinsky et al. San Antonio Breast Cancer Symposium 2020, GS3-00

RxPONDER clinical trial design


  • RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
  • The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score® result 0-25



Product Industry Theatre Video



"Yes or No? Answering CT and ET Questions Through a Case-based Discussion with the Oncotype DX® test" with speakers: Jeremy Force, DO, Alison Stopeck, MD and Christy Russell, MD.

Other presentations of interest on
the Oncotype DX® Breast Recurrence Score Test


SWOG S1007: adjuvant trial randomized ER+ patients who had a Recurrence Score <25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy


A prospective multicenter study evaluating the impact of the 21-gene Breast Recurrence Score upon physician treatment decision and cost in N+ breast cancer patients in Quebec
Abstract | Hassan

An analysis of the clinical and economic impact of the 21-gene Recurrence Score in invasive lobular early-stage breast cancer in Ireland
Abstract | Tharmabala

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Frist efficacy results from the ADAPT HR+/HER2- trial
Abstract | Harbeck

Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
Abstract | Sparano


ADAPTlate: A randomized, controlled, open-label, phase-III trial on adjuvant dynamic marker-adjusted personalized therapy comparing abemaciclib combined with standard adjuvant ER versus standard adjuvant ER in (clinical or genomic) high risk, HR+/HER2- early breast cancer
Abstract | Gluz

The feasibility of obtaining Oncotype DX Breast Recurrence Score results from the metastatic sites of patients with HR+ metastatic breast cancer
Abstract | Gemmill

Can genomic profiling eliminate the need for SLNB in ER+, T1-2 breast cancer
Abstract | Jackson

Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.